Research summaries
Plain-English synthesis of the published peptide combination literature, regulatory updates and notes from the laboratory.
2026-05-16
Peptide Stacking Fundamentals — Why Combinations Are Studied
An introduction to why peptide combinations are studied as research stacks, the mechanistic rationale for stacking, and how to read a stack page on this site.
2026-05-15
Reading a Peptide Research Study — A Glossary of Terms
How to interpret peptide research papers — methodology terms, study design language, and what 'translational potential' actually means.
2026-05-13
Why Animal-Model Peptide Studies Don't Translate to Human Outcomes
Most peptide research is rodent — what limits extrapolation to human pharmacokinetics, pharmacodynamics and clinical effect.
2026-05-10
The Sikiric Lab Body of Work on BPC-157 — A Citation Map
Predrag Sikiric's 30+ year research program on BPC-157 — what each major paper established, organised by tissue system.
2026-05-08
GLP-1 Receptor Biology Explained — From Exendin to Retatrutide
The evolution of the incretin class — GLP-1 alone, dual GIP/GLP-1 (Tirzepatide), to triple GIP/GLP-1/glucagon (Retatrutide). Mechanism and the rationale for adding receptors.
2026-05-05
Khavinson Bioregulators — The Soviet Peptide Tradition
Vladimir Khavinson's four-decade research program on short peptide bioregulators — Epitalon, Thymalin, Cortexin, Pinealon. Methodology and lifespan extension claims.
2026-05-02
Synergy of BPC-157 and TB-500 — A Review of the Combination Literature
Detailed review of the published in vitro and animal-model studies examining BPC-157 and TB-500 in combination, including Achilles-tendon, ligament-injury and ischaemia/reperfusion models.
2026-04-30
MHRA vs FDA vs EMA — Peptide Regulatory Comparison 2026
How the UK MHRA, US FDA and EU EMA each classify and regulate research-grade peptides in 2026. Approval pathways, enforcement priorities, import rules.
2026-04-22
UK Peptide Regulation 2026 — MHRA Position, POM Reclassifications, and Research-Use Boundaries
Where UK research peptide regulation stands in 2026 — the MHRA position, the GLP-1 reclassification picture, and what remains permissible for laboratory research use.
2026-03-15
GLP-1 / GIP / Glucagon Triple Agonists — Research Protocols for Retatrutide
Review of the published research protocols for Retatrutide and related triple GIP/GLP-1/glucagon agonists, including dosing escalation, side-effect management and comparative context.